Filing Details
- Accession Number:
- 0001209191-14-009945
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-02-12 19:57:53
- Reporting Period:
- 2014-02-10
- Filing Date:
- 2014-02-12
- Accepted Time:
- 2014-02-12 19:57:53
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1571498 | Epizyme Inc. | EPZM | Pharmaceutical Preparations (2834) | 261349956 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1502677 | Eric Hedrick | C/O Epizyme, Inc. 400 Technology Square Cambridge MA 02139 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock, Par Value $0.0001 Per Share | Acquisiton | 2014-02-10 | 13,500 | $2.19 | 13,500 | No | 4 | M | Direct | |
Common Stock, Par Value $0.0001 Per Share | Disposition | 2014-02-10 | 13,500 | $29.25 | 0 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2014-02-10 | 13,500 | $0.00 | 13,500 | $2.19 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
286,500 | 2022-06-06 | No | 4 | M | Direct |
Footnotes
- The sale transaction reported on this Form 4 was effected as a part of an underwritten public offering of common stock by Epizyme, Inc. with the Reporting Person as a selling stockholder in the offering.
- This option was granted on June 7, 2012 with respect to 300,000 shares of Common Stock, with 25% vesting on May 8, 2013 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter.